IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers

Development Candidate IDE251 - IDE251 is a potential first-in-class KAT6/7 dual inhibitor, designed to selectively target both KAT6 and KAT7 while sparing other structurally similar KAT family members [1][3] - The molecule demonstrates robust and durable monotherapy anti-tumor activity in preclinical models, particularly in biomarker-positive breast and lung cancer xenografts with 8p11 amplification [1][3] - IDE251 is targeted for evaluation in breast cancer and squamous non-small cell lung cancer (NSCLC) with 8p11 amplification, which occurs in approximately 15% of breast cancer patients and up to 17.5% in squamous NSCLC [1][2][4] Preclinical and Clinical Development - IND-enabling studies for IDE251 are progressing as planned, with the company targeting an Investigational New Drug (IND) submission to the FDA in 2025 [5] - The preclinical profile of IDE251 suggests an enriched response in 8p11 amplified cancers, with dual KAT6/7 inhibition showing superior anti-tumor activity compared to KAT6 inhibition alone [3][4] - IDE251 is being developed as a monotherapy for patients with breast and lung cancers with 8p11 amplification, with additional opportunities in lineage addiction settings [4] Company Overview - IDEAYA Biosciences is a precision medicine oncology company focused on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics [6] - The company integrates translational biomarker identification and validation with drug discovery to select patient populations most likely to benefit from its targeted therapies [6] - IDEAYA is applying its research and drug discovery capabilities to synthetic lethality, an emerging class of precision medicine targets [6]